Blinatumomab to prevent relapse after stem cell transplant for high-risk B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if a targeted drug, blinatumomab, can help prevent leukemia from coming back after a stem cell transplant. It is for people with high-risk B-cell acute lymphoblastic leukemia who have achieved remission but are at high risk of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 14 or older
- You have B-cell acute lymphoblastic leukemia that was at high risk of coming back before your stem cell transplant
- Your leukemia is currently in remission with no detectable cancer cells
- Your blood counts (neutrophils and platelets) are stable for at least a week
- You have not had severe graft-versus-host disease or uncontrolled chronic GVHD in the past 30 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests whether the drug blinatumomab, given after a stem cell transplant, can help prevent high-risk B-ALL from coming back. It is for people who have already had a transplant and meet certain health criteria.
This study tests if blinatumomab, an immunotherapy drug, can prevent B-cell acute lymphoblastic leukemia (B-ALL) from coming back in people who have already had a donor stem cell transplant. You may qualify if you had a relapse before transplant or had a positive minimal residual disease test, and if you are now in complete remission after the transplant.
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
This trial tests the drug blinatumomab for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after a stem cell transplant. The goal is to see if blinatumomab can safely treat the relapse.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
Hear when a new B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.